ZA200603124B - 1H-imidazole derivatives as cannabinoid receptor modulators - Google Patents
1H-imidazole derivatives as cannabinoid receptor modulators Download PDFInfo
- Publication number
- ZA200603124B ZA200603124B ZA200603124A ZA200603124A ZA200603124B ZA 200603124 B ZA200603124 B ZA 200603124B ZA 200603124 A ZA200603124 A ZA 200603124A ZA 200603124 A ZA200603124 A ZA 200603124A ZA 200603124 B ZA200603124 B ZA 200603124B
- Authority
- ZA
- South Africa
- Prior art keywords
- group
- disorders
- obesity
- composition
- substance
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title description 9
- 239000003520 cannabinoid receptor affecting agent Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 89
- 208000008589 Obesity Diseases 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 235000020824 obesity Nutrition 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- -1 methoxy, ethoxy, hydroxy, hydroxymethyl Chemical group 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 125000001153 fluoro group Chemical group F* 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 18
- 238000003786 synthesis reaction Methods 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 229930003827 cannabinoid Natural products 0.000 claims description 11
- 239000003557 cannabinoid Substances 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 230000000366 juvenile effect Effects 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 9
- 229940086609 Lipase inhibitor Drugs 0.000 claims description 9
- 208000006011 Stroke Diseases 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229940002612 prodrug Drugs 0.000 claims description 7
- 239000000651 prodrug Substances 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000002619 bicyclic group Chemical group 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000006413 ring segment Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 230000005062 synaptic transmission Effects 0.000 claims description 5
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 4
- 208000027520 Somatoform disease Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 230000002490 cerebral effect Effects 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 208000027753 pain disease Diseases 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000027559 Appetite disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 206010012335 Dependence Diseases 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 208000014094 Dystonic disease Diseases 0.000 claims description 3
- 206010014612 Encephalitis viral Diseases 0.000 claims description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 claims description 3
- 208000026139 Memory disease Diseases 0.000 claims description 3
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 3
- 206010028813 Nausea Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 3
- 208000016620 Tourette disease Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 206010044565 Tremor Diseases 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 206010013663 drug dependence Diseases 0.000 claims description 3
- 208000010118 dystonia Diseases 0.000 claims description 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 3
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000008693 nausea Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims description 3
- 229960001243 orlistat Drugs 0.000 claims description 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 3
- 208000015891 sexual disease Diseases 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 125000004306 triazinyl group Chemical group 0.000 claims description 3
- 201000002498 viral encephalitis Diseases 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004344 phenylpropyl group Chemical group 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims 6
- 235000014632 disordered eating Nutrition 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010019196 Head injury Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 102000005962 receptors Human genes 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 8
- 108050007331 Cannabinoid receptor Proteins 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 230000008485 antagonism Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 230000001270 agonistic effect Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 244000141218 Alpinia officinarum Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 229940127470 Lipase Inhibitors Drugs 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- HQVHOQAKMCMIIM-HXUWFJFHSA-N WIN 55212-2 Chemical compound C([C@@H]1COC=2C=CC=C3C(C(=O)C=4C5=CC=CC=C5C=CC=4)=C(N1C3=2)C)N1CCOCC1 HQVHOQAKMCMIIM-HXUWFJFHSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- FFBGKIOSTPTUEO-UHFFFAOYSA-N ethyl 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-(pyrrolidin-1-ylmethyl)imidazole-4-carboxylate Chemical compound C=1C=C(Cl)C=CC=1N1C(CN2CCCC2)=C(C(=O)OCC)N=C1C1=CC=C(Cl)C=C1Cl FFBGKIOSTPTUEO-UHFFFAOYSA-N 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000005567 liquid scintillation counting Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- LHYUTHUWHYHROB-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-[[ethyl(methyl)amino]methyl]-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(CN(C)CC)=C(C(=O)NN2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl LHYUTHUWHYHROB-UHFFFAOYSA-N 0.000 description 1
- SUKLGYYHKWBPAB-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-cyclohexyl-2-(2,4-dichlorophenyl)-5-[(dimethylamino)methyl]imidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(CN(C)C)=C(C(=O)NC2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl SUKLGYYHKWBPAB-UHFFFAOYSA-N 0.000 description 1
- YCVHHBIJYZETRR-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-cyclohexyl-2-(2,4-dichlorophenyl)imidazole-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NC2CCCCC2)=C1 YCVHHBIJYZETRR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- UNBMQQNYLCPCHS-UHFFFAOYSA-N Ebelactone B Natural products CCC(C)C(O)C(C)C(=O)C(C)C=C(C)CC(C)C1OC(=O)C1CC UNBMQQNYLCPCHS-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYISDADPVOHJBJ-UHFFFAOYSA-N Galangin 3-methyl ether Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(OC)=C1C1=CC=CC=C1 LYISDADPVOHJBJ-UHFFFAOYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000958270 Kitasatospora aburaviensis Species 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 241000946767 Streptomyces toxytricini Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000001774 alpinia officinarum Substances 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003375 cannabimimetic effect Effects 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- UNBMQQNYLCPCHS-VYNDPHDASA-N ebelactone b Chemical compound CC[C@@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)\C=C(/C)C[C@H](C)[C@@H]1OC(=O)[C@H]1CC UNBMQQNYLCPCHS-VYNDPHDASA-N 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
1H-IMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR
MODULATORS
The present invention relates to a group of 1H-imidazole derivatives which are modulators of cannabinoid receptors , to methods for the preparation of these compounds, to novel intermediates useful for the synthesis of said imidazole derivatives, to methods for the preparation of these intermediates, to pharmaceutical compositions containing one or more of these 1H-imidazole derivatives as active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of psychiatric and neurological disorders in which cannabinoid receptors are involved.
The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. A beneficial effect is disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. The invention also relates to the use of a compound of the invention for the manufacture of a medicament for treating or preventing a disease or condition. More particularly, the invention relates to a new use for the treatment of a disease or condition disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. In embodiments of the invention specific compounds disclosed herein are used for the manufacture of a medicament. 1H-Imidazole derivatives as CB receptor modulators are already known from WO 03/027076. However, the compounds described in WO 03/027076 are characterized by a relatively poor aqueous solubility. The goal of the present invention was to improve the aqueous solubility of 1H-imidazole derivatives whilst maintaining their cannabinoid receptor modulating activity. From the prior art it is not obvious how this goal should be achieved.
Surprisingly, it has now been found that the introduction of a 5-aminomethy! moiety in the 1H-imidazole core results in an enhanced aqueous solubility. Moreover, the derivatives containing said 5-aminomethyl moiety retain their cannabinoid receptor modulating activity, such as receptor antagonism, receptor inverse agonism or receptor (partial) agonism.
The invention relates to compounds of the general formula (1)
NV] '
AX _~R, 0)
R NR,
R, wherein: - Rand Ry are the same or different and represent phenyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl or triazinyl, which groups may be substituted with 1, 2, 3 or 4 substituents Y, which can be the same or different, selected from the group consisting of methyl, ethyl, propyl, methoxy, ethoxy, hydroxy, hydroxymethyl, hydroxyethyl, chloro, iodo, bromo, fluoro, trifluoromethyl, trifluoromethoxy, methyisulfonyl, phenyl and cyano, or R represents naphtyl, or R represents a C1 branched or linear alkyl group, a C1; cycloalkyl group, C7 cycloalkyl-C,., alkyl group, a Csgbranche d or linear heteroalkyl group, a Cs; heterocycloalky! group or a C.; heterocycioalkyl -Cs.; alkyl group which groups may be substituted with a fluoro atom or a CF; or OH group, - Ryand R; are the same or different and represent H, a Cys branched or linear alkyl group which alkyl group may be substituted with a hydroxy group, or 1-3 fluoro atoms or,
R. represents a branched or linear C 13 alkoxy group, with the proviso that Rs; represents H or a methyl group - Rp and R; - together with the nitrogen atom to which they are bonded - form a saturated or unsaturated non-aromatic, monocyclic or bicyclic, heterocyclic group having 5 to 10 ring atoms which heterocyclic group contains one or two ring heteroatoms from the group (N, O, S), which heteroatoms can be the same or different, which heterocyclic group may be substituted with a C+.; alkyl group, a hydroxy group, or a fluoro atom, - Ry represents H or a methyl, ethyl, propyl, isopropyl or n-butyl group, - Xrepresents one of the subgroups (i), or (ii),
0 0
LL, Loe \ R, 0) (ii) wherein: - Rs represents a hydrogen atom, or a Ca.5 branched or linear alkyl group, C1.- alkyl-SO,-C1.4- alkyl group, Cs cycloalkyl group, Csz-cycloalkyl-Cy.-alkyl group,
Cs7-heterocycloalkyl-Cy.2-alkyl group which groups may be substituted with a hydroxy, methyl or trifluoromethyl group or a fluoro atom and which Cs heterocycloalkyl-C.-alkyl group contains one or two heteroatoms from the group (O, N, S), or Rs represents a phenyl, benzyl, phenethyl or phenylpropy! group which may be substituted on their phenyl ring with 1-3 substituents Y, wherein Y has the abovementioned meaning, or Rs represents a pyridyl or thienyl group, - Re represents a hydrogen atom or a branched or linear C+.; alkyl group, - R; represents hydrogen, a branched or linear C 14 alkyl or Cy g-cycloalkyl-C;.o- alkyl group, branched or linear Cg alkoxy, Cs cycloalkyl, Cs 1 bicycloalkyl, Cs. bicycloalkyl-C1.; alkyl, Cs. tricycloal kyl, C 4 tricycloalkyimethyl, which groups may contain one or more heteroatoms from the group (O, N, S) and which groups may be substituted with a hydroxy group, 1-3 methyl groups, an ethyl group or 1- 3 fluoro atoms, or R; represents a phenyl, phenylamino, phenoxy, benzyl, phenethy! or phenylpropyl group, optionally substituted on their phenyl ring with 1-3 substituents Y, wherein Y has the abovementioned meaning, or R; represents a pyridyl or thienyl group, or Ry represents a group NRgRg wherein
Rs and Ry - together with the nitrogen atom to which they are attached -form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having 4 to 10 ring atoms, which heterocyclic group contains one or more heteroatoms from the group (O, N, S) and which heterocyclic group may be substituted with a branched or linear C13 alkyl, phenyl, hydroxy or trifluoromethyt group or a fluoro atom, or
Rs and R; — together with the nitrogen atom to which they are attached - form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having 4 to 10 ring atoms, which heterocyclic group contains one or more heteroatoms from the group (O, N, S) and which heterocyclic group may be substituted with a branched or linear Cy alkyl, phenyl, amino, hydroxy or trifluoromethyl group or a fluoro atom, and pharmacologically acceptable salts and prodrugs thereof.
To the invention belong all compounds having formula (I), racemates, mixtures of diastereomers and the individual stereoisomers. Thus compounds in which the substituents on potentially asymmetrical carbon atoms are in either the R- configuration or the S-configuration belong to the invention.
Prodrugs are therapeutic agents which are inactive per se but are transformed into one or more active metabolites. Prodrugs are bioreversible derivatives of drug molecules used to overcome some barriers to the utility of the parent drug molecule.
These barriers include, but are not limited to, solubility, permeability, stability, presystemic metabolism and targeting limitations (Medicinal Chemistry: Principles and Practice, 1994, ISBN 0-85186-494-5, Ed. F. D. King, p. 215; J. Stella, “ Prodrugs as therapeutics”, Expert Opin. Ther. Patents, 14(3), 277-280, 2004; P. Ettmayer et al., “Lessons leamed from marketed and investigational prodrugs”, J.Med.Chem., 47, 2393-2404, 2004). Pro-drugs, i.e. compounds which when administered to humans by any known route, are metabolised to compounds having formula (1), belong to the invention. In particular this relates to compounds with primary or secondary amino or hydroxy groups. Such compounds can be reacted with organic acids to yield compounds having formula (1) wherein an additional group is present which is easily removed after administration, for instance, but not limited to amidine, enamine, a
Mannich base, a hydroxyl-methylene derivative, an O-(acyloxy-methylene carbamate) derivative, carbamate, ester, amide or enaminone.
The invention particularly relates to compounds having formula (I) wherein X represents the subgroup (ii), and all other symbols have the meanings as described above.
More particular the invention relates to compounds of formula (1) wherein X represents the subgroup (ii), and R represents phenyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl or triazinyl, which groups may be substituted with 1, 2, 3 or 4 substituents Y, which can be the same or different, from the group methyl, ethyl, propyl, methoxy, ethoxy, hydroxy, hydroxymethyl, hydroxyethyl, chloro, iodo, bromo, fluoro, trifluoromethyl, trifluoromethoxy, methylsulfonyl, phenyl or cyano, or R represents naphtyl, and all other symbols have the meanings as described above.
GENERAL ASPECTS OF SYNTHESES
Compounds of formula (I) and the synthetic intermediates of formula (il) and (Vh respectively may be prepared by a variety of methodologies. The synthesis of 5 structurally related imidazoles as cannabinoid receptor modulators has been described in WO 03/027076 and WO 03/063781. The synthesis of structurally related imidazoles as anti-obesity compounds has also been described in WO 03/040107.
The selection of the particular method depends on factors such as the compatibility of functional groups with the reagents used, the possibility to use protecting groups, catalysts, activating and coupling reagents and the ultimate structural features present in the final compound being prepared. More information on activating and coupling methods of amines to carboxylic acids can be found in: a) M.Bodanszky and A. Bodanszky: The Practice of Peptide Synthesis, 16 Springer-Verlag, New York, 1994; ISBN: 0-387-57505-7: b) K.Akaji etal., Tetrahedron Lett, 1994, 35, 3315-3318); c) F.Albericio et al., Tetrahedron Lett.,1997, 38, 4853-4856).
More information on trimethylaluminum AI(CH3); promoted amidation reactions of esters can be found in: J. I. Levin, E. Turos, S. M. Weinreb, Synth Commun. 1982, 12, 989-993.). For more information on nucleophiles, electrophiles and the leaving group concept see: M. B. Smith and J. March: Advanced organic chemistry, p. 275, 5" ed., (2001) John Wiley & Sons, New York, ISBN: 0-471-58589-0). More information on addition and subsequent removal of protective groups in organic synthesis can be found in: T.W. Greene and P.G.M. Wuts, “Protective Groups in
Organic Synthesis”, third edition, John Wiley & Sons, Inc., New York, 1999.
A suitable synthesis for the compounds of the invention is the following:
Synthesis route A
Reaction of a compound having formula (If) 0
OR a ’ 0 red (
R Rq wherein R, Ry, R4 have the meanings given above and Ry represents a branched or linear alkyl group (C4) or benzyl group with a regioselective brominating compound such as N-bromosuccinimide (NBS) in an organic solvent such as CCl, in the presence of a free-radical initiator such as dibenzoyl peroxide can give a compound of formula (1) 0]
OR,,
P \ 1)
RN Br (
RR, wherein R, R;, R4 and Ryo have the meanings given above. Reaction of a compound having formula (Ill) with an amine of general formula R,R3NH can give a compound of general formula (IV) oO
OR
Ny j Vv rR, NR,R, (Vv)
RR, wherein R, Ry, R2, R3, Ry and Ryo have the meanings given above.
Compounds of general formula (I'V) which have been obtained according to synthesis route A can be converted to compounds of general formula (I) wherein X represents subgroup (ii), analogously to the procedures described in WO 03/027076.
Synthesis route B
Reaction of a compound having formula (IV) wherein R, R4, Ry, Rs and R4 have the meanings given above and Ry, represents a hydrogen atom
0
ORy,
A (IV rR, NR,R, ) with N-methoxy-N-methylamine can give a compound of formula (V), 0 N y,
Ty o- Vv)
Ry NRR,
R Ry wherein R, Ry, Ry, Ry; and R, have the meanings given above. Reaction of a compound having formula (V) with an organometallic compound of general formula
Re-MgBr (a Grignard reagent) or Rs-Li (an organo lithium reagent) can give a compound of general formula (1), wherein X represents subgroup (i). Such a reaction is preferably carried out under N, in an anhydrous inert organic solvent.
Synthesis route C 2-Aryl-(1H}imidazole-4-carboxylates can be obtained according to the procedure described in Tetrahedron Lett. (1971), 18, 1439-1440 (Heindel and Chun).
Subsequent derivatisation (for example, an N-arylation or N-alkylation reaction) of the proper imidazole N-atom can produce compounds having formula (V1). Reaction of a compound having formula (V1) 0]
OR
, { ;
Ry (v1)
R wherein R and Ry have the meanings given above and Ry, represents a branched or linear alky! group (C1.4) or benzyl group, with a non-nucleophilic base such as lithium diisopropylamide (LDA), followed by an electrophile such as formic acid ethyl ester in an inert anhydrous organic solvent such as THF can give a compound of general formula (VII)
0]
N OR, ro \ vi)
Ry Y
R R, wherein R, Ry, R4 and Ry, have the meanings given above in this synthetic route.
Reductive amination of a compound having general formula (VII) with an amine of general formula R;R3NH in the presence of a reducing agent such as NaCNBH 3 can give a compound of general formula (IV) 0]
OR i \% rR, NR,R, (iv)
R R, wherein R, Ry, Raz, Rs, Rs and Ry have the meanings given above in this synthetic route.
Compounds of general formula (IV) which have been obtained according to synthesis route C can be converted to compounds of general formula (I) wherein X represents subgroup (ii), analogously to the procedures described in WO 03/027076.
Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by mixing a compound of the present invention with a suitable acid, for instance an inorganic acid such as hydrochloric acid, or with an organic acid.
Due to their cannabinoid receptor modulating activity the compounds according to the invention are suitable for use in the treatment of psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, in particular juvenile obesity and drug induced obesity, addiction, appetence, drug dependence and neurological disorders such as neurodegenerative disorders, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson's disease, Alzheimer's
: ] : disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, cerebral apoplexy, craniocerebral frauma, stroke, spinal cord injury, neuroinflammatory disorders, plaque sclerosis, viral encephalitis, demyelinisation related disorders, as well as for the treatment of pain disorders, including neuropathic 9 pain disorders, and other diseases involving cannabinoid neurotransmission, including the treatment of septic shock, glaucoma, cancer, diabetes, emesis, nausea, asthma, respiratory diseases, gastrointestinal disorders, sexual disorders, liver cirrhosis, gastric ulcers, diarrhoea and cardiovascular disorders.
The cannabinoid receptor modulating activity of the compounds of the invention makes them particularly useful in the treatment of obesity, juvenile obesity and drug induced obesity, when used in combination with lip ase inhibitors. Specific examples of compounds which can be used in such combination preparations are (but not restricted to) the synthetic lipase inhibitor orlistat, lipase inhibitors isolated from micro organisms such as lipstatin (from Streptomyces toxytricini), ebelactone B 16 (from Streptomyces aburaviensis), synthetic derivatives of these compounds, as well as extracts of plants known to possess lipase inhibitory activity, for instance extracts of Alpinia officinarum or compounds isolated from such extracts like 3- methylethergalangin (from A. officinarum).
The compounds of the invention can be brought into forms suitable for administration by means of usual processes using auxiliary substances and/or liquid or solid carrier materials.
Compounds of the invention are generally administered as pharmaceutical compositions which are important and novel embodiments of the invention because of the presence of the compounds, more particularly specific compounds disclosed herein. Types of pharmaceutical compositions that may be used include but are not limited to tablets, chewable tablets, capsules, solutions, parenteral solutions, suppositories, suspensions, and other types disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. In embodiments of the invention, a pharmaceutical pack or kit is provided comprising one or more containers filled with one or more of the ingredients of a pharmaceutical composition of the invention. Associated with such container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals products, which notice reflects approval by the agency of manufacture, use, or sale for human or veterinary administration.
PHARMACOLOGICAL METHODS
In vitro affinity for cannabinoid-CB; receptors
The affinity of the compounds of the invention for cannabinoid CB ; receptors can be determined using membrane preparations of Chinese hamster ovary (CHO) cells in which the human cannabinoid CB; receptor is stably transfected in conjunction with [PHICP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [*HJHigand, with or without addition of compounds of the invention, separation of bound and free ligand is performed by filtration over glassfiber filters. Radioactivity on the fitter is measured by liquid scintillation counting.
In vitro affinity for cannabinoid-CB; receptors
The affinity of the compounds of the invention for cannabinoid CB , receptors can be determined using membrane preparations of Chinese hamster ovary (CHO) cells in which the human cannabinoid CB, receptor is stably transfected in conjunction with [PHICP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [*HJHigand, with or without addition of compounds of the invention, separation of bound and free ligand is performed by filtration over glassfiber filters. Radioactivity on the filter is measured by liquid scintillation counting.
In vitro cannabinoid-CB, receptor antagonism
In vitro CB; receptor antagonism can be assessed with the human CB, receptor cloned in Chinese hamster ovary (CHO) cells. CHO cells are grown in a Dulbecco's
Modified Eagle's medium (DMEM) culture medium, supplemented with 10% heat- inactivated fetal calf serum. Medium is aspirated and replaced by DMEM, without fetal calf serum, but containing [*H]-arachidonic acid and incubated overnight in a cell culture stove (5% CO./95% air; 37 °C; water-saturated atmosphere). During this period [*H]-arachidonic acid is incorporated in membrane phospholipids. On the test day, medium is aspirated and cells are washed three times using 0.5 mL DMEM, containing 0.2% bovine serum albumin (BSA). Stimulation of the CB receptor by
WIN 55,212-2 leads to activation of PLA followed by release of [*H]-arachidonic acid into the medium. This WIN 55,212-2-induced release is concentration -dependently antagonized by CB, receptor antagonists.
In vivo cannabinoid-CB receptor antagonism
In vivo CB4 antagonism can be assessed with the CP-55,940-induced hypotension test in rat. Male normotensive rats (225-300 g; Harlan, Horst, The Netherlands) are anaesthetized with pentobarbital (80 mg/kg ip). Blood pressure is measured, via a cannula inserted into the left carotid artery, by means of a Spectramed DTX -plus pressure transducer (Spectramed B.V., Bilthoven, The Netherlands). After amplification by a Nihon Kohden Carrier Amplifier (Type AP-621G; Nihon Kohden
B.V., Amsterdam, The Netherlands), the blood pressure signal is registered on a personal computer (Compaq Deskpro 386s), by means of a Po-Ne-Mah data- acquisition program (Po-Ne-Mah Inc., Storrs, USA). Heart rate is derived from the pulsatile pressure signal. All compounds are administered orally as a microsuspension in 1% methylcellulose 30 minutes before induction of the anesthesia which is 60 minutes prior to administration of the CB receptor agonist
CP-55,940. The injection volume is 10 mig. After haemodynamic stabilization the
CB; receptor agonist CP-55,940 (0.1 mg/kg i.v.) is administered and the hypotensive effect established. (Wagner, J. A; Jarai, Z.; Batkai, S.; Kunos, G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid
CB1 receptors. Eur. J. Pharmacol. 2001, 423, 203-210); Lange, J. H. M. et al., J.
Med. Chem. 2004, 47, 627-643.
In vivo cannabinoid-CB, receptor (partial) agonistic activity
Cannabinoid receptor agonistic or partial agonistic activity of compounds of the invention can be determined according to published methods, such as assessment of in vivo cannabimimetic effects (Wiley, J. L. et al,, J. Pharmacol. Exp. Ther. 2001, 296, 1013).
DETERMINATION OF AQUEOUS SOLUBILITY
The compounds are dissolved in DMSO to give 10 mg/mi stock solutions. These stock solutions are divided over several plates. Several diluted concentrations are made with DMSO to 5, 2.5, 1.25, 0.625 and 0.3125 mg/ml, respectively. The stock solution and each derived concentration from this stock solution is taken and diluted 100 fold with water or with water containing a buffer. In every case this gives an aqueous solution which contains 1 % DMSO (v/v) and 100, 50, 25, 12.5 and 6.25 and
3.125 ug compound /ml, respectively. The formation of a precipitate is determined in each plate. The measurements were performed at pH= 7, applying a HEPES buffer and at pH= 2, applying hydrochloric acid. Aqueous solubility is expressed in ug/ml in the table below.
The specific compounds of which the synthesis is described below are intended to further illustrate the invention in more detail, and therefore are not deemed to restrict the scope of the invention in any way.
EXAMPLE 1: SYNTHESES OF SPECIFIC COMPOUNDS
Synthesis of compound 1
Part A: Ethyl S-bromomethyl-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H- 16 imidazole-d-carboxylate. To a magnetically stired mixture of ethyl 1-(4- chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyi-1H-imidazole-4-carboxylate (2.05 g, 5.00 mmol) in CCl4 (25 mL) was added N-bromosuccinimide (NBS) (1.34 g, 7.53 mmol) and dibenzoy! peroxide (10.0 mg, assay 75%, 0.0310 mmol) and the resulting mixture was refluxed for 38 h. The formed precipitate was removed by filtration. The filtrate was successively washed with brine and water, dried over MgSO, filtered and concentrated in vacuo. The residue was purified by flash chromatography (CHCl /acetone = 98/2 (viv) to give ethyl 5-bromomethyi-1-(4-chloropheny!)-2-(2,4- dichlorophenyl)-1H-imidazole-4-carboxylate (1.29 g, 53 % yield) as an amorphous solid, "H-NMR (200 MHz, CDCl3): § 1.45{ J =7 Hz, 3H), 4.48 (q, J = 7 Hz, 2H), 4.72 (s,2H),7.18-7.43 (m, 7TH).
Part B: To a magnetically stirred solution of ethyl 5-bromomethyi-1-(4-chlorophenyl}- 2-(2,4-dichlorophenyl}-1H-imidazole-4-carboxylate (11.69 g, 23.9 mmol) in acetonitrile (40 ml) is added diisopropylethylamine (DIPEA) (5.2 ml, 30 mmol) and pyrrolidine (1.7 g, 23.9 mmol) and the resulting solution is reacted at room temperature for 2 hours. Water (250 ml) is added and the resulting mixture is extracted three times with dichloromethane. The collected dichloromethane layers are dried over Na ;SQ,, filtered and concentrated in vacuo. Subsequent purification with flash chromatography (petroleum ether/EtOAc = 20/80 (viv)) gives ethyl 1-(4- chlorophenyl)-2-(2,4-dichloro-phenyl)-5-{pyrrolidin-1-ylmethyl)-1H-imidazole4- carboxylate (3.7 gram, 32 % vield). "H-NMR (200 MHz, CDCl): §1.42 (t, J = 7 Hz,
3H), 1.62-1.72 (m, 4H), 2.42-2.50 (m, 4H), 3.83 (s, 2H), 4.43 (q, J = 7 Hz, 2H), 7.17- 7.40 (m, TH).
Part C: Cyclohexylamine (0.91 mi, 8 mmol) is dissolved in dichloromethane (20 mi) 9 and (CHskAl (4 ml of a 2 M solution in heptane, 8 mmol) is added. The resulting mixture is stirred for 10 minutes at room temperature and ethyl 1-(4-chlorophenyl)-2- (2,4-dichlorophenyl)-5-(pyrrolidin-1-ylmethyl)-1H-imidazole-4-carboxylate (1.8 gram , 3.8 mmol) is added. The resulting mixture is stirred at room temperature for 16 hours, poured into an aqueous NaHCO; solution, stirred for 30 minutes and filtered over hyflo. The filtrated is twice extracted with dichloromethane. The organic layers are dried over Na,SO,, filtered and concentrated in vacuo. Subsequent purification with flash chromatography (dichloromethane/methanol = 98/2 (v/v) gives N-cyclohexyi-1- (4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-(pyrrolidin-1-yimethyl)-1H-imidazole-4- carboxamide, compound 1 (1.06 gram, 53 % yield). Melting point: 155-157 °C. 16 lo] rr
Naa N ole
Cl
Analogously, the following compounds 2 — 6 were prepared : 2 2 N-cyclohexyi-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-(N-ethyl,N- methylaminomethyl)-1H-imidazole-4-carboxamide. Melting point: 135-136 °C. 0] cl -
Saf a N \
Cl 3. N-(piperidin-1-yi}-1-{4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-(N,N- dimethylaminomethyl)-1H-imidazole-4-carboxamide. Melting point: 163-166 []
C.
» 0 cl N+) if a N cl 4. N-cyclohexyl-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-(N,N- dimethylaminomethyl)-1H-imidazole-4-carboxamide. "H-NMR (400 MHz,
CDCl3): $1.12-1.68 (m, 6H), 1.72-1.80 (m, 2H), 1.99-2.06 (m, 2H), 2.18 (s, 6H), 3.65 (s, 2H), 3.88-4.00 (m, 1H), 7.22-7.37 (m, 8H). 0
RET
7 \ c N
Cl 5. N-(piperidin-1-yl)-1-(4~chlorophenyl)-2-(2,4-dichlorophenyl)-5-(pyrrolidin-1- ylmethy)-1H-imidazole-4-carboxamide. 2 HCI. "H-NMR (400 MHz, DMSO-d): § 1.46-1.56 (m, 2H), 1.79-1.96 (m, 8H), 2.90-3.00 (m, 2H), 3.26-3.50 (m, 6H), 4.57 (br s, 2H), 7.45-7.60 (m, 6H), 7.70 (d, J = 8 Hz, 1H), 10.95 (br s, 2H). 0 a {0
Oy
N c 0 & 2HCI cl 6. N-(piperidin-1-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-(N-ethyl,N- methylaminomethyl)-1H-imidazole-4-carboxamide. "H-NMR (400 MHz,
CDCl3): § 0.86 (t, J = 7 Hz, 3H), 1.38-1.46 (m, 2H), 1.72-1.78 (m, 4H), 2.14 (s, 3H), 2.36 (q, J = 7 Hz, 2H), 2.82-2.86 (m, 4H), 3.72 (s, 2H), 7.21-7.31 (m, 6H), 7.34 (d, J = 2 Hz, 1H), 8.16 (br s, 1H).
0) of N {3 0 N \ cl
EXAMPLE 2: DETERMINATION OF AQUEOUS SOLUBILITIES 9 Aqueous solubilities of two of the compounds of general formula (1), the compounds 1 and 4, and the compound 1-(4-chlorophenyl)-2-(2,4~dichloro-phenyl)-N-cyclohexyl- 1H-imidazole-4-carboxamide ( compound 3 from WO 03/063781) were determined according to the procedure described above. The results are shown in Table 1.
Table 1: aqueous solubility (expressed in pg/ml)
Compound name Aqueous solubility in pg/ml at:
TT ToH=2 JpH=7
EE FO EN
N-cyclohexyl-1-(4-chlorophenyi)-2-(2,4-dichloropheny!)- 5-(pyrrolidin-1-ylmethyl)-1H-imidazole-4-carboxamide compound 1
N-cyclohexyl-1-(4-chlorophenyi)-2-(2,4-dichlorophenyl)- 5-(N,N-dimethylaminomethyl)-1H-imidazole-4- carboxamide (compound 4
N-cyclohexyl-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)- 1H-imidazole-4-carboxamide (WO 03/063781
EXAMPLE 3: PHARMACOLOGICAL DATA
Pharmacological test results of a subset of the compounds of the invention, obtained with the assay described above, are given in table 2 below:
Table 2: pharmacological data
T Human cannabinoid-CB; receptor vitro affinity . pK value (Compound | ~~ rr
Compound? | ~~ 81 (Compound2 | ~~ 82
Compoundd | ~~ 70
Compound 4 [Compounds | 63 (Compound6 [68
Claims (26)
1. Compounds of the general formula (1) 1 ’ AK on (0) R NR Ry ’ wherein: - Rand R, are the same or different and represent phenyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridaziny! or triazinyt, which groups may be substituted with 1, 2, 3 or 4 substituents Y, which can be the same or different, selected from the group consisting of methyl, ethyl, propyl, methoxy, ethoxy, hydroxy, hydroxymethyl, hydroxyethyl, chloro, iodo, bromo, fluoro, trifluoromethyl, trifluoromethoxy, methylsulfonyl, phenyl and cyano, or R represents naphtyl, or R represents a C1. branched or linear alkyl group, a C3 cycloalkyl group, Cs cycloalkyl-C.2 alkyl group, a Cs branched or linear heteroalkyl group, a Cs heterocycloalkyl group or a Cs heterocycloalkyl -C,., alkyl group which groups may be substituted with a fluoro atom or a CF 3 or OH group, - Roand R; are the same or different and represent H, a Cbranched or linear alkyl group which alkyl group may be substituted with a hydroxy group, or 1-3 fluoro atoms or, R, represents a branched or linear C1.; alkoxy group, with the proviso that R; represents H or a methyl group, or R; and R; - together with the nitrogen atom to which they are bonded - form a saturated or unsaturated non-aromatic, monocyclic or bicyclic, heterocyclic group having 5 to 10 ring atoms which heterocyclic group contains one or two "ring heteroatoms from the group (N, O, S), which heteroatoms can be the same or different, which heterocyclic group may be substituted with a C3 alkyl group, a hydroxy group, or a fluoro atom, - Ry represents H or a methyl, ethyl, propyl, isopropyl or n-butyl group, - Xrepresents one of the subgroups (i), or (ii),
0 0 EE “R, (i) (ii) wherein:
5 - Rs represents a hydrogen atom, or a Cy. branched or linear alkyl group, C1.> alkyl-SO2-C1.4- alkyl group, Caz cycloalkyl group, Cs;-cycloalkyl-Cs.-alkyl group, Csr-heterocycloalkyl-C+.o-alkyl group which groups may be substituted with a hydroxy, methyl or trifluoromethyl group or a fluoro atom and which Cs. rheterocycloalkyl-Cy.o-alky! group contains one or two heteroatoms from the group (O, N, S), or Rs represents a phenyl, benzyl, phenethyl or phenyipropyl group which may be substituted on their phenyl ring with 1-3 substituents Y, wherein Y has the abovementioned meaning, or Rs represents a pyridyl or thienyl group,
- Rs represents a hydrogen atom or a branched or linear C 4.3 alkyl group,
- Ry represents hydrogen, a branched or linear C4 alkyl or Cg-cycloalkyl-Cyo- alkyl group, branched or linear C4 alkoxy, Ca cycloalkyl, Cs. bicycloalkyi, Cs-10 bicycloalkyl -C,., alkyl, Cg.19 tricycloalkyl, Ceo tricycioalkylmethyl, which groups may contain one or more heteroatoms from the group (O, N, S) and which groups may be substituted with a hydroxy group, 1-3 methyl groups, an ethyl group or 1-3 fluoro atoms, or R; represents a phenyl, phenylamino, phenoxy, benzyl, phenethyl or phenylpropyl group, optionally substituted on their phenyl ring with 1-3 substituents Y, wherein Y has the abovementioned meaning, or Rr represents a pyridyl or thienyl group, or R; represents a group NRgRg wherein
- Rg and Ry - together with the nitrogen atom to which they are attached -form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having 4 to 10 ring atoms, which heterocyclic group contains one or more heteroatoms from the group (O, N, S) and which heterocyclic group may be substituted with a branched or finear C3 alkyl, phenyl, hydroxy or trifluoromethyl group or a fluoro atom, or - Re and R; — together with the nitrogen atom to which they are attached - form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group having 4 to 10 ring atoms, which heterocyclic group contains one or more heteroatoms from the group (O, N, S) and which heterocyclic group may be substituted with a branched or linear C3 alkyl, phenyl, amino, hydroxy or trifluoromethyl group or a fluoro atom, and all stereoisomers, as well as pharmacologically acceptable salts and prodrugs thereof.
2. Compounds as claimed in claim 1 having general formula (I) wherein X represents the subgroup (ii), and all other symbols have the meanings as given in claim 1.
3. Compounds as claimed in claim 1 having formula (1) wherein X represents the subgroup (ii), R represents phenyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl or triazinyl, which groups may be substituted with 1, 2, 3 or 4 substituents Y, which can be the same or different, from the group methyl, ethyl, propyl, methoxy, ethoxy, hydroxy, hydroxymethyl, hydroxyethyl, chloro, iodo, bromo, fluoro, trifluoromethyl, trifluoromethoxy, methyisulfonyl, phenyl or cyano, or R represents naphtyl, and all other symbols have the meanings as given in claim 1,
4. Compounds of the general formula (IV) 0 OR N { 10 rR, NRR, (v) RR, wherein R, Ry, Ry, R; and Ry have the meanings given in claim 1 and Ry represents a hydrogen atom, a linear or branched C4 alkyl group or a benzyl group, such compounds being useful in the synthesis of compounds of the general formula (1).
5. Compounds of the general formula (VI) 0} OR NT J Rel ong RR, wherein Ry and R4 have the meanings given above in claim 1 and R represents a Cie branched or linear alkyl group, a C,; cycloalkyl group, Cs; cycloalkyl -Cy., alkyl group, a C34 branched or linear heteroalkyl group, a Cs heterocycloalkyl group or a Cs heterocycloalkyl-C,, alkyl group which groups may be substituted with a fluoro atom or a CF; or OH group, and Ry, represents a branched or linear alkyl group (C+.) or benzyl group.
6. Pharmaceutical compositions containing at least one compound as claimed in any one of the claims 1-3 as an active component.
7. A compound as claimed in any of the claims 1-3, or a salt thereof, for use as a medicament
8. Use of a compound as claimed in any one of the claims 1-3 for the preparation of a pharmaceutical composition for the treatment of disorders involving cannabinoid neurotransmission.
9. Use as claimed in claim 8, characterized in that said disorders are psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, in particular juvenile obesity and drug induced obesity, addiction, appetence, drug dependence and neurological disorders such as neurodegenerative disorders, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson's disease, Alzheimer’s disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, cerebral apoplexy, craniocerebral trauma, stroke, spinal cord injury, neuroinflammatory disorders, plaque sclerosis, viral encephalitis, demyelinisation related disorders, as well as for the treatment of pain disorders, including neuropathic pain disorders, and other diseases involving cannabinoid
PCT/EP2004/052575 ” neurotransmission, including the treatment of septic shock, glaucoma, cancer, diabetes, emesis, nausea, asthma, respiratory diseases, gastrointestinal disorders, sexual disorders, liver cirrhosis, gastric ulcers, diarrhoea and cardiovascular disorders.
10. Use as claimed in claim 8, characterized in that said disorders are eating disorders, in particular obesity, juvenile obesity and drug induced obesity.
11. Use of a compound as claimed in claim 1 and at least one lipase inhibitor for the preparation of a pharmaceutical composition for the treatment of eating disorders, in particular obesity, juvenile obesity and drug induced obesity.
12. Use of a compound as claimed in claim 1 in the manufacture of a medicament for use with at least one lipase inhibitor, for the treatment of eating disorders, in particular obesity, juvenile obesity and drug induced obesity.
13. Use as claimed in claim 11, or claim 12 characterized in that said lipase inhibitor is orlistat or lipstatin.
14. Use of a compound as claimed in any of the claims 1-3, or a salt thereof, in the manufacture of a medicament for treating a disease, illness, disorder or condition.
15. A substance or composition for use in a method of treatment, said substance or compasition comprising a compound as claimed in any one of the claims 1-3, or a salt thereof, and said method comprising administering said substance or composition.
16. A substance or composition for use in a method for the treatment of disorders involving cannabinoid neurotransmission, said substance or composition comprising a compound as claimed in any of the claims 1-3, and said method comprising administering said substance or composition.
17. A substance or composition for use in a method of treatment as claimed in claim 16, characterized in that said disorders are psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, in particular juvenile obesity and drug induced obesity, AMENDED SHEET
PCT/EP2004/052575 ® 2 addiction, appetence, drug dependence and neurological disorders such as neurodegenerative disorders, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, cerebral apoplexy, craniocerebral trauma, stroke, spinal cord injury, neuroinflammatory disorders, plaque sclerosis, viral encephalitis, demyelinisation related disorders, as well as for the treatment of pain disorders, including neuropathic pain disorders, and other diseases involving cannabinoid neurotransmission, including the treatment of septic shock, glaucoma, cancer, diabetes, emesis, nausea, asthma, respiratory diseases, gastrointestinal disorders, sexual disorders, liver cirrhosis, gastric ulcers, diarrhoea and cardiovascular disorders.
18. A substance or composition for use in a method of treatment as claimed in claim 16, characterized in that said disorders are eating disorders, in particular obesity, juvenile obesity and drug induced obesity.
19. A substance or composition for use in a method for the treatment of eating disorders, in particular obesity, juvenile obesity and drug induced obesity, said substance or composition comprising a compound as claimed in claim 1 and at least one lipase inhibitor, and said method comprising administering said substance or composition.
20. A substance or composition for use with at least one lipase inhibitor in a method for the treatment of eating disorders, in particular obesity, juvenile obesity and drug induced obesity, said substance or composition comprising a compound as claimed in claim 1, and said method comprising administering said substance or composition and said lipase inhibitor.
21. A substance or composition for use in a method of treatment as claimed in claim 19 or claim 20, characterized in that said lipase inhibitor is orlistat or lipstatin.
22. A compound as claimed in any one of claims 1 to 5 or 7, substantially as herein described and illustrated. AMENDED SHEET
PCT/EP2004/052575 ’s
23. A composition as claimed in claim 6, substantially as herein described and illustrated.
24. Use as claimed in any one of claims 8 to 14, substantially as herein described and illustrated.
25. A substance or composition for use in a method of treatment as claimed in any one of claims 15 to 21, substantially as herein described and illustrated.
26. A new compound, a new composition, a new use of a compound as claimed in any one of claims 1 to 3, a new use of a compound as claimed in claim 1 and at least one lipase inhibitor, or a substance or composition for a new use in a method of treatment, substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03103867 | 2003-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200603124B true ZA200603124B (en) | 2007-09-26 |
Family
ID=34924117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200603124A ZA200603124B (en) | 2003-10-20 | 2006-04-19 | 1H-imidazole derivatives as cannabinoid receptor modulators |
Country Status (7)
Country | Link |
---|---|
CN (1) | CN100556894C (en) |
AR (1) | AR046182A1 (en) |
HK (1) | HK1091823A1 (en) |
SA (1) | SA04250339B1 (en) |
TW (1) | TW200524908A (en) |
UA (1) | UA82908C2 (en) |
ZA (1) | ZA200603124B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101302200B (en) * | 2007-05-09 | 2011-04-20 | 上海医药工业研究院 | Preparation of N-piperidine subbase-5-(4-chlorphenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-formamide |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
WO2003063781A2 (en) * | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
-
2004
- 2004-10-15 TW TW93131338A patent/TW200524908A/en unknown
- 2004-10-15 AR ARP040103749 patent/AR046182A1/en not_active Application Discontinuation
- 2004-10-17 SA SA4250339A patent/SA04250339B1/en unknown
- 2004-10-19 CN CNB2004800243493A patent/CN100556894C/en not_active Expired - Fee Related
- 2004-10-19 UA UAA200605398A patent/UA82908C2/en unknown
-
2006
- 2006-04-19 ZA ZA200603124A patent/ZA200603124B/en unknown
- 2006-11-09 HK HK06112346.0A patent/HK1091823A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
SA04250339B1 (en) | 2008-07-19 |
UA82908C2 (en) | 2008-05-26 |
HK1091823A1 (en) | 2007-01-26 |
CN100556894C (en) | 2009-11-04 |
AR046182A1 (en) | 2005-11-30 |
TW200524908A (en) | 2005-08-01 |
CN1842520A (en) | 2006-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1713475B1 (en) | 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
US7109216B2 (en) | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | |
AU2005214084B2 (en) | Imidazoline derivatives having CB1-antagonistic activity | |
US7745476B2 (en) | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
IL173436A (en) | 1h-imidazole derivatives, intermediates thereof, pharmaceutical compositions comprising them and their use as cannabinoid receptor modulators | |
US7498348B2 (en) | 1 H-imidazole derivatives as cannabinoid receptor modulators | |
US7524867B2 (en) | Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity | |
EP1756066B1 (en) | Tetrasubstituted imidazole derivatives as cannabinoid cb1 receptor modulators with a high cb1/cb2 receptor subtype selectivity | |
ZA200603124B (en) | 1H-imidazole derivatives as cannabinoid receptor modulators | |
US7173044B2 (en) | Imidazoline derivatives having CB1-antagonistic activity | |
TW200528442A (en) | 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having CB1-antagonistic activity |